| Pair Name | Lycopene, T0901317 | ||
| Phytochemical Name | Lycopene (PubChem CID: 446925 ) | ||
| Anticancer drug Name | T0901317 (PubChem CID: 447912 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Lycopene, T0901317 | |||
| Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
| Biological Phenomena | Inhibition-->Cell proliferation | |||
| Gene Regulation | Up-regulation | Expression | ABCA1 | hsa19 |
| Up-regulation | Expression | NR1H3 | hsa10062 | |
| Up-regulation | Expression | PPARG | hsa5468 | |
| In Vitro Model | DU145 | Prostate carcinoma | Homo sapiens (Human) | CVCL_0105 |
| PC-3 | Prostate carcinoma | Homo sapiens (Human) | CVCL_0035 | |
| Result | These results demonstrate that lycopene can inhibit DU145 cell proliferation via PPARγ-LXRα-ABCA1 pathway and that lycopene and T0901317 exhibit synergistic effects. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Lycopene and the LXRα agonist T0901317 synergistically inhibit the proliferation of androgen-independent prostate cancer cells via the PPARγ-LXRα-ABCA1 pathway. J Nutr Biochem. 2012 Sep;23(9):1155-62. doi: 10.1016/j.jnutbio.2011.06.009. | Click |
